Table 1: Demographics of study subjects by aspirin using conditions between 1997 and 2008 in Taiwan.

Descriptor Nonaspirin users among T2DM patients Aspirin users among T2DM patients value
10720(%)2876(%)

Age group∖mean ± SD<0.001
 50–59350732.761821.5<0.001
 60–69446941.7126544.0
 70–79218220.481028.2
 ≥805625.21836.4
Gender
 Male519448.5147951.4<0.005
 Female552651.5139748.6
Stroke3853.643515.1<0.001
 No stroke1033596.4244184.9<0.001
 Haemorrhagic stroke1231.1491.7<0.018
 Ischemic stroke1541.42629.1<0.001
 Transient ischemic stroke690.6873.0<0.001
 Unclassified930.91133.9<0.001
Antidiabetes drug type
 Never use702665.588030.6<0.001
 Acarbose3573.329210.2<0.001
 Metformin229121.4130845.5<0.001
 Thiazolidinedione (TZD)1961.81414.9<0.001
 Sulfonylureas256323.9148151.5<0.001
 Meglitinide2462.31936.7<0.001
 Insulin1010.91113.9<0.001
Statin type
 Never use981191.5219376.3<0.001
 Atorvastatin3523.329610.3<0.001
 Fluvastatin1041.0933.2<0.001
 Lovastatin2091.9983.4<0.001
 Pravastatin1081.0672.3<0.001
 Rosuvastatin1021.01144.0<0.001
 Simvastatin1721.61334.6<0.001
Hypertensive drug type
 Never use641859.950917.7<0.001
 Alpha blocker5455.129410.2<0.001
 ARB141513.2111638.8<0.001
 ACEI107310.075526.3<0.001
 Beta blocker164915.4108737.8<0.001
 CCB256023.9156754.5<0.001
 Diuretics7857.349817.3<0.001
CCI score ∖ mean ± SD1.1 ± 1.31.6 ± 1.5<0.001
 CCI score of 0437540.878227.2<0.001
 CCI score of 1, 2481344.9146550.9
 CCI score of 3, 4125111.750017.4
 CCI score of ≥52812.61294.5
Chronic diseases
 No chronic disease404637.774425.9<0.001
 Arthropathy4143.91324.60.078
 Cardiovascular148013.875026.1<0.001
 Gastrointestinal160014.942814.90.954
 Hepatic235822.087330.4<0.001
 Neoplasm3132.9973.40.208
 Neurologic460.4220.80.024
 Pulmonary382035.6122442.6<0.001
 Renal10659.943915.3<0.001

Diagnosed T2DM patients who did not use aspirin before the end of follow-up date.
The aspirin regular user is the patient who uses aspirin continuously at least over one year in the follow-up time that nearly 2 aspirin prescriptions cannot exceed 120 days. This group of diagnosed T2DM patients is aspirin regular user group.
Wilcoxon rank sum test and Pearson’s Chi-square test.
The case number is calculated before patient’s index date. The index date of patient who never uses aspirin before the end of follow-up date is the T2DM diagnosed date. The index date of patient who is aspirin regular user is the date of starting to take aspirin regularly.
The case number is the regular use of the specific drugs before patient’s end date of observation.
Charlson comorbidity index (CCI). The diagnoses recorded in the National Health Insurance Research Database before the index date are used to calculate CCI score. We exclude the diagnosis of diabetes mellitus and stroke from CCI score calculation, because these two disease entities are considered separately.
SD: standard deviation, T2DM: type 2 diabetes mellitus, ARB: angiotensin II receptor blockers, ACEI: angiotensin converting enzyme inhibitors, and CCB: calcium channel blocker.